Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

ClinicalTrials.gov ID: NCT04410445

Public ClinicalTrials.gov record NCT04410445. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 11:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main purpose of this study is to compare the efficacy of bempegaldesleukin plus nivolumab versus nivolumab in patients with completely resected Stage IIIA/B/C/D, or Stage IV cutaneous melanoma who are at high risk for recurrence.

Study identification

NCT ID
NCT04410445
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Nektar Therapeutics
Industry
Enrollment
765 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 27, 2020 (Actual)
Primary completion
Sep 22, 2022 (Actual)
Completion
Sep 22, 2022 (Actual)
Last update posted
Apr 21, 2023

2020 – 2022

United States locations

U.S. sites
62
U.S. states
28
U.S. cities
47
Facility City State ZIP Site status
Honor Health Scottsdale Arizona 85258 —
Banner MD Anderson Cancer Center Little Rock Arkansas 72205 —
Kaiser Foundation Hospital, Inpatient Pharmacy Anaheim California 92805 —
Kaiser Permanente Fontana California 92335 —
St. Joseph Heritage Healthcare Fullerton California 92835 —
Hematology Oncology Medical Group of Orange County, Inc. Orange California 92868 —
University of California Irvine Orange California 92868 —
Emad Ibrahim, MD, Inc Redlands California 92373 —
Kaiser Permanente Riverside California 92505 —
Southern California Permanente Medical Group Riverside California 92505 —
San Francisco Oncology Associates San Francisco California 94115 —
California Cancer Associates for Research and Excellence San Marcos California 92069 —
Kaiser Permanente San Marcos California 92078 —
Angeles Clinic and Research Institute Santa Monica California 90404 —
John Wayne Cancer Institute Santa Monica California 90404 —
Rocky Mountain Cancer Centers (Littleton) - USOR Aurora Colorado 80012 —
University of Colorado - Cancer Center - PPDS Aurora Colorado 80045 —
MedStar Georgetown University Hospital Washington D.C. District of Columbia 20007 —
Orlando Health Cancer Institute Longwood Florida 32750 —
Rush University Medical Center Chicago Illinois 60612 —
Goshen Center For Cancer Care Goshen Indiana 46526 —
University of Kentucky Lexington Kentucky 40536 —
Ochsner Clinic Foundation New Orleans Louisiana 70121 —
Massachusetts General Hospital Boston Massachusetts 02114 —
Mayo Clinic - PIN Rochester Minnesota 55905 —
Washington University School of Medicine St Louis Missouri 63110 —
Frontier Cancer Center and Blood Institute Billings Montana 59102 —
Nebraska Cancer Specialists Omaha Nebraska 68130 —
Nebraska Methodist Hospital Omaha Nebraska 68130 —
University of Nebraska Medical Center Omaha Nebraska 68198 —
Hackensack University Medical Center Hackensack New Jersey 07601 —
Atlantic Health System Morristown New Jersey 07960 —
NYU Langone Medical Center New York New York 10016 —
Columbia University Medical Center - PIN New York New York 10021 —
Icahn School of Medicine at Mount Sinai New York New York 10029 —
University of North Carolina at Chapel Hill Chapel Hill North Carolina 32750 —
Duke Cancer Institute Durham North Carolina 27710 —
University Hospitals Cleveland Medical Center Cleveland Ohio 44106 —
The Cleveland Clinic Foundation Cleveland Ohio 44195 —
Providence Cancer Institute, Franz Clinic Portland Oregon 97213 —
Oregon Health and Science University Portland Oregon 97216 —
Lehigh Valley Physician Group (LVPG) - Hematology Oncology Allentown Pennsylvania 18103 —
Penn State Milton S Hershey Medical Center Hershey Pennsylvania 17033 —
Jefferson University Hospital Philadelphia Pennsylvania 19107 —
H Lee Moffitt Cancer Center and Research Institute Pittsburgh Pennsylvania 15232 —
Hillman Cancer Center Pittsburgh Pennsylvania 15232 —
Prisma Health Cancer Institute Greenville South Carolina 29605 —
SCRI Tennessee Oncology Chattanooga Chattanooga Tennessee 37404 —
University of Tennessee Medical Center Knoxville Tennessee 37920 —
SCRI Tennessee Oncology Nashville Nashville Tennessee 37203 —
Vanderbilt University Medical Center Nashville Tennessee 37232 —
Department of Pharmacy Investigational Drug Services Dallas Texas 75235 —
Texas Oncology (Loop) - USOR Dallas Texas 75246 —
University of Texas Southwestern Medical Center Dallas Texas 75390 —
MD Anderson Cancer Center Houston Texas 77030 —
Utah Cancer Specialists (Salt Lake City) Salt Lake City Utah 90603 —
University of Virginia Cancer Center Charlottesville Virginia 22903 —
Inova Schar Cancer Institute Fairfax Virginia 22031 —
Blue Ridge Cancer Care - USOR Roanoke Virginia 24014 —
Seattle Cancer Care Alliance Seattle Washington 98109 —
Northwest Medical Specialties Tacoma Washington 98405 —
University of Wisconsin Madison Wisconsin 53792 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 150 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04410445, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 21, 2023 · Synced Oct 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04410445 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →